Letybo and Dysport are both botulinum toxin type A, and in the United States both are approved for one cosmetic use: the frown lines between the eyebrows.
The honest summary is that one is new and one is established. Letybo was approved in the US in 2024 and launched here in 2025. Dysport has been available since 2009 and also has approvals for medical conditions.
Their doses are very different numbers for the same job. Letybo uses 20 units for frown lines. Dysport uses 50. That does not mean Dysport is stronger — the two brands measure units differently, and neither number converts into the other.
Made by Hugel, a Korean company. Widely used in Asia before it reached the US.
On the US market since 2009, and in Europe for longer.
No medical approvals in the US.
The cosmetic approval is written for adults under 65.
The toxin comes wrapped in helper proteins.
Also wrapped, in a mix of sizes.
Letybo beat a placebo in all three.
The label reports up to four months of effect.
Letybo is new in the United States, not new in the world. It has been used in South Korea and other markets for years, and its US approval rested on three trials in more than 1,200 people.
What being new does mean is that there is less long-run US safety reporting to draw on, and fewer injectors have used it hundreds of times. That is a fair thing to weigh, and a fair thing to ask your injector about directly: how many times have you used this one?
Letybo's three trials are a useful lesson in reading these numbers.
The same product, at the same dose, produced success rates ranging from 47% to 65% across the three trials. Nothing about the drug changed, and the three trials used an identical design and an identical way of scoring success. What differed was who took part, where, and how big each trial was — enough on its own to move the number eighteen points.
That is the size of the gap you can get from trial design alone — and it is bigger than most of the differences people argue about between brands. So when a chart shows one toxin at 55% and another at 65%, and those numbers came from different studies, the chart is not telling you which one works better.
Go to an emergency department or call 911. Do not wait for a call back. These are rare, but they are the symptoms named in the FDA boxed warning that every botulinum toxin product carries, deaths have been reported, and they can begin hours or even weeks after treatment.
If a vision change is sudden or severe, seek urgent care rather than waiting.